{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:09Z","timestamp":1761518829803},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bisphosphonates are the most effective agents for treating and\/or preventing complications of bone metastases and are the standard of care in this setting. Currently, four bisphosphonates are available for metastatic bone disease (MBD): clodronate, pamidronate, zoledronic acid, and ibandronate. Although all four of these bisphosphonates have been shown to reduce the incidence of skeletal-related events in patients with bone metastases, there are substantial differences among these agents in their potency, dose and route of administration, and side effects. Ibandronate and zoledronic acid, the two newer aminobisphosphonates, appear to have similar biochemical efficacies when phase III trial data are compared. Both agents were equally effective in reducing markers of bone resorption in the only prospective comparative trial carried out to date, but no data on relative clinical efficacy are available from head-to-head comparisons. Both the oral and i.v. formulations of ibandronate have also shown long-term efficacy in managing metastatic bone pain (MBP), but the onset of action of standard bisphosphonate treatment is not sufficient when rapid relief of pain is required. Because of its favorable renal safety profile, i.v. ibandronate can be administered daily for 3 days, as a so-called \u201cloading dose.\u201d This dosing regimen has allowed rapid and effective relief of MBP without the unwanted side effects associated with opioids and other analgesics. Ibandronate is thus an effective, flexible, and well-tolerated bisphosphonate that can meet the varying requirements of patients with MBD.<\/jats:p>","DOI":"10.1634\/theoncologist.11-90001-27","type":"journal-article","created":{"date-parts":[[2006,9,14]],"date-time":"2006-09-14T01:12:26Z","timestamp":1158196346000},"page":"27-33","source":"Crossref","is-referenced-by-count":21,"title":["Ibandronate: Its Role in Metastatic Breast Cancer"],"prefix":"10.1093","volume":"11","author":[{"given":"David","family":"Cameron","sequence":"first","affiliation":[{"name":"a Western General Hospital, Edinburgh, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fallon","sequence":"additional","affiliation":[{"name":"a Western General Hospital, Edinburgh, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Diel","sequence":"additional","affiliation":[{"name":"b Institute for Gynecological Oncology, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"2021122208444413500_R1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122208444413500_R2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CBC.2000.n.003","article-title":"Treatment of metastatic bone disease in breast cancer: bisphosphonates","volume":"1","author":"Diel","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"2021122208444413500_R3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"key":"2021122208444413500_R4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1399-6576.1982.tb01852.x","article-title":"Management of cancer pain","volume":"74","author":"Bonica","year":"1982","journal-title":"Acta Anaesthesiol Scand Suppl"},{"key":"2021122208444413500_R5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122208444413500_R6","first-page":"46","article-title":"Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate","volume":"22","author":"Body","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208444413500_R7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"2021122208444413500_R8","first-page":"S69","article-title":"Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data","volume":"38","author":"Body","year":"2006","journal-title":"Bone"},{"key":"2021122208444413500_R9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122208444413500_R10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122208444413500_R11","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208444413500_R12","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122208444413500_R13","first-page":"S91","article-title":"Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison","volume":"34","author":"Tripathy","year":"2004","journal-title":"Bone"},{"issue":"suppl 1","key":"2021122208444413500_R14","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bone.2006.01.047","article-title":"Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial","volume":"38","author":"Rivkin","year":"2006","journal-title":"Bone"},{"issue":"suppl 1","key":"2021122208444413500_R15","first-page":"S57","article-title":"Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI ZICE trial","volume":"38","author":"Barrett-Lee","year":"2006","journal-title":"Bone"},{"key":"2021122208444413500_R16","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122208444413500_R17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"2021122208444413500_R18","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208444413500_R19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"suppl 5","key":"2021122208444413500_R20","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","article-title":"High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer","volume":"1","author":"Heidenreich","year":"2003","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"2021122208444413500_R21","first-page":"S69","article-title":"Loading-dose ibandronate with maintenance dosing for the palliation of metastatic bone pain: the Bon-I-Pain and Bon-O-Pain trials","volume":"38","author":"Body","year":"2006","journal-title":"Bone"},{"key":"2021122208444413500_R22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2354.2005.00641.x","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur J Cancer Care"},{"issue":"suppl 1","key":"2021122208444413500_R23","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.bone.2006.01.012","article-title":"Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase II\/III trials","volume":"38","author":"Bergstr\u00f6m","year":"2006","journal-title":"Bone"},{"key":"2021122208444413500_R24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122208444413500_R25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00044011-200626010-00006","article-title":"Safety of oral ibandronate in the treatment of bone metastases from breast cancer","volume":"26","author":"McLachlan","year":"2006","journal-title":"Clin Drug Invest"},{"key":"2021122208444413500_R26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced a vascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122208444413500_R27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122208444413500_R28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208444413500_R29","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208444413500_R30","article-title":"Bisphosphonates and jaw osteonecrosis: updated experience with ibandronate","volume-title":"Presented at the 31st European Society for Medical Oncology Congress","author":"Chukwujindu","year":"2006"},{"key":"2021122208444413500_R31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2021122208444413500_R32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021122208444413500_R33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122208444413500_R34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfg044","article-title":"Pamidronate-induced tubu-lointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism","volume":"18","author":"Buysschaert","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2021122208444413500_R35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","article-title":"Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions","volume":"119","author":"Jones","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122208444413500_R36","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122208444413500_R37","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208444413500_R38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122208444413500_R39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122208444413500_R40","volume-title":"Zometa\u00ae (zoledronic acid). US summary of product characteristics","author":"Novartis Pharmaceuticals Corporation","year":"2004"},{"key":"2021122208444413500_R41","volume-title":"Zometa\u00ae (zoledronic acid). EU summary of product characteristics","author":"Novartis International AG","year":"2005"},{"key":"2021122208444413500_R42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1359-6349(04)90866-X","article-title":"Renal safety of ibandronate in patients with bone metastases from breast cancer: phase III trial results","volume":"2","author":"Bell","year":"2004","journal-title":"EJC Suppl"},{"key":"2021122208444413500_R43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V106.11.3459.3459","article-title":"Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration","volume":"106","author":"Henrich","year":"2005","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.11-90001-27","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.11-90001-27","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/S1\/27\/41851381\/oncolo_11_s1_27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/S1\/27\/41851381\/oncolo_11_s1_27.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:19:19Z","timestamp":1640186359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/11\/S1\/27\/6397132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":43,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2006,9,1]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.11-90001-27","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,9,1]]},"published":{"date-parts":[[2006,9,1]]}}}